Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB–IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial - 16/08/11
, Rafael Rosell, ProfMD b, Mario De Lena, MD c, Francesco Carpagnano, MD d, Rodryg Ramlau, MD e, Jose Luis Gonzáles-Larriba, MD f, Tomasz Grodzki, MD g, Jose Rodrigues Pereira, MD h, Alain Le Groumellec, MD i, Vito Lorusso, ProfMD j, Claude Clary, MD k, Antonio J Torres, MD l, Jabrail Dahabreh, MD m, Pierre-Jean Souquet, MD n, Julio Astudillo, MD o, Pierre Fournel, MD p, Angel Artal-Cortes, MD q, Jacek Jassem, ProfMD r, Leona Koubkova, MD s, Patricia His t, Marcello Riggi, MD t, Patrick Hurteloup, MD tSummary |
Background |
Whether adjuvant chemotherapy improves survival of patients with non-small-cell lung cancer (NSCLC) is not known. We aimed to compare the effect of adjuvant vinorelbine plus cisplatin versus observation on survival in patients with completely resected NSCLC.
Methods |
840 patients with stage IB–IIIA NSCLC from 101 centres in 14 countries were randomly assigned to observation (n=433) or to 30 mg/m2 vinorelbine plus 100 mg/m2 cisplatin (n=407). Postoperative radiotherapy was not mandatory and was undertaken according to every centre’s policy. The primary endpoint was overall survival. Analysis was by intention to treat. This trial is registered as an International Standard Randomised Controlled Trial, number ISRCTN95053737.
Findings |
367 patients in the chemotherapy group and 431 in the control group received their assigned treatment. 301 (36%) patients had stage IB disease, 203 (24%) had stage II disease, and 325 (39%) had stage IIIA disease. Tolerance to chemotherapy mainly included neutropenia in 335 (92%) patients and febrile neutropenia in 34 (9%); seven (2%) toxic deaths were also recorded. Compliance was greater with cisplatin than with vinorelbine (median dose intensity 89% [range 17–108] vs 59% [17–100]). After a median follow-up of 76 months (range 43–116), median survival was 65·7 months (95% CI 47·9–88·5) in the chemotherapy group and 43·7 (35·7–52·3) months in the observation group. Adjusted risk for death was significantly reduced in patients assigned chemotherapy compared with controls (hazard ratio 0·80 [95% CI 0·66–0·96]; p=0·017). Overall survival at 5 years with chemotherapy improved by 8·6%, which was maintained at 7 years (8·4%).
Interpretation |
Adjuvant vinorelbine plus cisplatin extends survival in patients with completely resected NSCLC, better defining indication of adjuvant chemotherapy.
Le texte complet de cet article est disponible en PDF.Plan
Vol 7 - N° 9
P. 719-727 - septembre 2006 Retour au numéro
Article précédent
- What’s in a face?
- Mark R Katz
- Staging of carcinoid tumours with 18F-DOPA PET: a prospective, diagnostic accuracy study
- Klaas P Koopmans, Elisabeth GE de Vries, Ido P Kema, Philip H Elsinga, Oliver C Neels, Wim J Sluiter, Anouk NA van der Horst-Schrivers, Pieter L Jager
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?